Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Tuesday

Posted by on May 5th, 2026

Kezar Life Sciences (NASDAQ:KZR – Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.98) per share and revenue of $0.50 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.60). On average, analysts expect Kezar Life Sciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kezar Life Sciences Trading Down 0.1%

Shares of KZR traded down $0.01 during trading hours on Tuesday, reaching $7.38. The company had a trading volume of 25,281 shares, compared to its average volume of 64,829. The firm has a 50 day simple moving average of $7.06 and a 200-day simple moving average of $6.49. The company has a market capitalization of $54.41 million, a price-to-earnings ratio of -0.96 and a beta of 0.40. Kezar Life Sciences has a 12-month low of $3.53 and a 12-month high of $7.55.

Hedge Funds Weigh In On Kezar Life Sciences

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Kezar Life Sciences by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 68,167 shares of the company’s stock valued at $429,000 after purchasing an additional 2,665 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Kezar Life Sciences by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after purchasing an additional 3,312 shares in the last quarter. State Street Corp increased its stake in Kezar Life Sciences by 28.4% in the 4th quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after purchasing an additional 6,000 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in Kezar Life Sciences by 25.9% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,638 shares of the company’s stock valued at $325,000 after purchasing an additional 10,638 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Kezar Life Sciences in the 3rd quarter valued at approximately $51,000. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

(Get Free Report)

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.

Read More

Earnings History for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.